8-K: PACS Group Reports Strong Q1 2026 Results, Raises Guidance

PACS Group, Inc. announced robust first quarter 2026 financial results, exceeding expectations with significant increases in revenue and net income, leading to an upward revision of full-year Adjusted EBITDA guidance.

Summary

• PACS Group, Inc. reported first quarter 2026 revenue of $1.42 billion, an 11.2% increase year-over-year.
• Net income surged by 184.2% to $80.7 million, up from $28.4 million in the prior year.
• Adjusted EBITDA reached $170.4 million, a 74.6% increase from $97.6 million, benefiting from $16.3 million in WQIP payments.
• Same-store SNF revenue grew 8.0%, with occupancy improving to 90.9% and skilled mix increasing.
• The company raised its full-year 2026 Adjusted EBITDA guidance to $605 million - $625 million, an increase from $555 million - $575 million.
• A new $250 million share repurchase authorization was approved.
• Cash provided by operating activities was $236.3 million.
• Available liquidity stood at $795.1 million as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant growth in key financial metrics, an upward revision of guidance, and a new share repurchase authorization indicating confidence in future performance and commitment to shareholder value.

Positives

• Significant revenue growth of 11.2% to $1.42 billion in Q1 2026.
• Net income more than doubled, increasing by 184.2% to $80.7 million.
• Adjusted EBITDA saw a substantial increase of 74.6% to $170.4 million.
• Occupancy rates improved to 90.9% on a same-store basis.
• Skilled mix increased by 90 basis points in nursing patient days.
• Full-year Adjusted EBITDA guidance was raised significantly.
• Strong cash flow from operations of $236.3 million.
• A new $250 million share repurchase program was authorized.

Negatives

• New facility revenue decreased by 32.3% to $213.4 million.
• New facility occupancy rate was 82.7%, lower than mature and ramping facilities.
• The company is excluding contributions from future acquisitions from its updated guidance, despite a healthy pipeline.

Risks

• Dependence on reimbursement from third-party payors and potential changes in payment methodologies.
• Increased competition for and shortages of skilled personnel, potentially raising labor costs.
• State efforts to regulate healthcare services or facility construction could impair expansion.
• Failure to attract patients or compete effectively with other providers may reduce revenue.
• Reviews and audits of care delivery, recordkeeping, and billing may result in repayments.
• Litigation and claims common in the industry could lead to significant costs.
• Material weaknesses in internal control over financial reporting could impair reporting and investor confidence.
• Extensive and complex laws and regulations govern the industry, and noncompliance or changes could require significant expenditures.

Future Outlook

The company has increased its full-year 2026 Adjusted EBITDA guidance to a range of $605 million to $625 million, up from $555 million to $575 million, representing approximately 22% growth at the midpoint over 2025. Revenue guidance remains at $5.65 billion to $5.75 billion. This updated guidance excludes contributions from future acquisitions.

Management Comments

• "I'm very pleased with our first quarter results and the hard work of our teams in delivering these outcomes. Our performance reflects PACSs core strengths—our commitment to care, clinical excellence, operational quality, industry-leading talent, and a strategy built for sustainable growth," said Jason Murray, PACSs Chief Executive Officer.
• "The improvements we continue to see, both large and small, across all of our organization, demonstrate the underlying strength of our business model and our teams relentless execution in advancing our mission."
• "Our first quarter results reflect strong underlying operating performance across the portfolio, with growth in all our key metrics. This performance continues to be driven by solid execution within our ramping and mature cohorts, alongside improving occupancy and skilled mix," said Carey Hendrickson, PACSs Chief Financial Officer.
• "We also strengthened our balance sheet during the quarter, increasing revolver availability and maintaining low net leverage of approximately 0.1x, while deploying $86.5 million into strategic real estate investments. Overall, we believe the quarter highlights both the earnings power of the platform and our disciplined approach to capital allocation."
• "Given our strong start to the year and continued excellent performance across both ramping and mature cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance..."
• "Establishing a share repurchase authorization provides us with an important capital allocation tool and the flexibility to repurchase shares opportunistically when conditions warrant. Had the authorization been in place during the first quarter, there were periods where we believe it would have been appropriate to deploy capital in this way."

Industry Context

StockSavvy.ai notes that PACS Group's strong Q1 2026 performance, particularly the significant increase in net income and Adjusted EBITDA, along with the upward revision of full-year guidance, positions it favorably within the post-acute healthcare sector. The company's focus on operational improvements, skilled mix enhancement, and occupancy growth aligns with key industry trends aimed at improving quality of care and financial performance.

Comparison to Industry Standards

• PACS Group's Q1 2026 occupancy rate of 90.8% significantly exceeds the industry average of 79%.
• Mature facilities achieved an average CMS Quality Measure Star rating of 4.4, indicating strong quality performance relative to industry benchmarks.
• The company's skilled mix by nursing patient days of 30.5% shows improvement and is a key metric for revenue generation in the post-acute sector, where higher acuity patients generally command higher reimbursement rates.

Legal Proceedings

• The filing references ongoing investigations that incurred legal and professional fees in prior periods, but does not detail current or new legal proceedings.

Stakeholder Impact

• Shareholders: Benefit from strong financial performance, increased guidance, and a new $250 million share repurchase authorization, potentially leading to increased stock value.
• Employees: Continued focus on talent and operational quality may lead to a stable work environment and opportunities for growth.
• Creditors: Low net leverage and strong cash flow provide confidence in the company's ability to meet its debt obligations.

Next Steps

• Conference call and webcast to discuss Q1 2026 results on May 12, 2026.
• Continue executing on strategy of expanding footprint through leasing and acquiring real estate.
• Actively evaluate opportunities to acquire underperforming operations.
• Selectively deploy capital to grow owned real estate portfolio.
• Evaluate potential acquisition transactions that align with strategic and financial criteria.
• Potentially utilize the new $250 million share repurchase authorization.

Key Dates

Recommendation

The company delivered exceptionally strong Q1 results, significantly exceeding prior expectations and leading to a substantial increase in full-year guidance. The improved operational metrics, robust cash flow, and initiation of a large share repurchase program all point to a highly positive outlook and significant undervaluation relative to its growth trajectory and profitability.

Keywords

PACS Group, Post-Acute Healthcare, Skilled Nursing Facilities, Q1 2026 Earnings, Financial Results, EBITDA Guidance, Share Repurchase, Healthcare Operations